MX2020007882A - Variantes fc con unión mejorada a fcrn y semivida prolongada. - Google Patents

Variantes fc con unión mejorada a fcrn y semivida prolongada.

Info

Publication number
MX2020007882A
MX2020007882A MX2020007882A MX2020007882A MX2020007882A MX 2020007882 A MX2020007882 A MX 2020007882A MX 2020007882 A MX2020007882 A MX 2020007882A MX 2020007882 A MX2020007882 A MX 2020007882A MX 2020007882 A MX2020007882 A MX 2020007882A
Authority
MX
Mexico
Prior art keywords
binding polypeptides
fcrn
variants
life
longer half
Prior art date
Application number
MX2020007882A
Other languages
English (en)
Inventor
Huawei Qiu
Brian Mackness
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65520379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020007882(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2020007882A publication Critical patent/MX2020007882A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción proporciona polipéptidos de unión (p. ej., anticuerpos e inmunoadhesinas) que comprenden un dominio de Fc modificado. La presente descripción también proporciona ácidos nucleicos que codifican los polipéptidos de unión, vectores de expresión recombinantes, y células huésped para preparar tales polipéptidos de unión. También se proporcionan métodos de uso de los polipéptidos de unión descritos en este documento para tratar la enfermedad.
MX2020007882A 2018-01-26 2019-01-25 Variantes fc con unión mejorada a fcrn y semivida prolongada. MX2020007882A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622468P 2018-01-26 2018-01-26
PCT/US2019/015204 WO2019147973A1 (en) 2018-01-26 2019-01-25 Fc variants with enhanced binding to fcrn and prolonged half-life

Publications (1)

Publication Number Publication Date
MX2020007882A true MX2020007882A (es) 2020-12-03

Family

ID=65520379

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020007882A MX2020007882A (es) 2018-01-26 2019-01-25 Variantes fc con unión mejorada a fcrn y semivida prolongada.
MX2025009543A MX2025009543A (es) 2018-01-26 2020-07-24 Variantes fc con union mejorada a fcrn y semivida prolongada

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025009543A MX2025009543A (es) 2018-01-26 2020-07-24 Variantes fc con union mejorada a fcrn y semivida prolongada

Country Status (16)

Country Link
US (1) US20190263934A1 (es)
EP (1) EP3743441A1 (es)
JP (3) JP7399880B2 (es)
KR (2) KR102748986B1 (es)
CN (2) CN111788221B (es)
AU (2) AU2019212638B2 (es)
BR (1) BR112020015006A2 (es)
CA (1) CA3089602A1 (es)
CO (1) CO2020010269A2 (es)
IL (2) IL318916A (es)
MX (2) MX2020007882A (es)
MY (1) MY203898A (es)
PH (1) PH12020551134A1 (es)
SG (1) SG11202006905YA (es)
TW (1) TW201940512A (es)
WO (1) WO2019147973A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7399880B2 (ja) * 2018-01-26 2023-12-18 ジェンザイム・コーポレーション ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
EP4004039A2 (en) * 2019-07-25 2022-06-01 Genzyme Corporation Methods of treating antibody-mediated disorders with fcrn antagonists
CN114746120B (zh) 2019-10-03 2024-07-30 Atyr医药公司 包含抗nrp2抗体的组合物和方法
US11434276B2 (en) * 2020-05-11 2022-09-06 Invetx, Inc. Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use
MX2023004933A (es) * 2020-10-29 2023-06-06 Formycon Ag Proteinas de fusion de ace2 y usos de las mismas.
US12297273B2 (en) 2021-05-27 2025-05-13 Sanofi Fc variant with enhanced affinity to Fc receptors and improved thermal stability
MX2024002150A (es) 2021-08-20 2024-03-08 Intervet Int Bv Anticuerpos y proteinas de fusion de igg con una semivida prolongada.
WO2023244276A2 (en) * 2021-10-13 2023-12-21 The Wistar Institute Of Anatomy And Biology DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS
IL317227A (en) 2022-05-27 2025-01-01 Sanofi Sa Combined natural killer (NK) cells bind to NKP46 and BCMA variants with FC engineering
CN116162171B (zh) * 2022-10-13 2025-06-03 深圳市百士通科技开发有限公司 抗体突变方法在治疗性抗体药物中的应用
KR20250094703A (ko) 2022-10-25 2025-06-25 아블린쓰 엔.브이. 향상된 효과기 기능을 갖는 당조작된 Fc 변이체 폴리펩타이드
AR131281A1 (es) 2022-12-05 2025-03-05 Sanofi Sa Proteínas de unión al receptor de transferrina
US20250154262A1 (en) 2023-10-25 2025-05-15 Ablynx N.V. Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING
WO2025101094A1 (en) * 2023-11-08 2025-05-15 Ооо «Geropharm» Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
WO2026022712A1 (en) 2024-07-23 2026-01-29 Sanofi Cereblon ligase modulator and bcma nk cell engager combination therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
HU230769B1 (hu) * 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
KR20070057839A (ko) * 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2373689A1 (en) * 2008-12-12 2011-10-12 MedImmune, LLC Crystals and structure of a human igg fc variant with enhanced fcrn binding
HRP20160422T1 (hr) * 2009-12-23 2016-05-20 Synimmune Gmbh Protutijela protiv flt3 postupci njihove upotrebe
WO2011089211A1 (en) * 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
JP6322411B2 (ja) * 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
RU2687043C2 (ru) * 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
RS59340B1 (sr) * 2014-11-06 2019-10-31 Hoffmann La Roche Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
EP3218402A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-il-1beta antibodies and methods of use
SG11201900616UA (en) * 2016-08-02 2019-02-27 Visterra Inc Engineered polypeptides and uses thereof
JP7399880B2 (ja) * 2018-01-26 2023-12-18 ジェンザイム・コーポレーション ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体

Also Published As

Publication number Publication date
MY203898A (en) 2024-07-23
KR20250008975A (ko) 2025-01-16
EP3743441A1 (en) 2020-12-02
BR112020015006A2 (pt) 2020-12-29
KR102748986B1 (ko) 2025-01-02
AU2019212638A1 (en) 2020-09-17
CN111788221A (zh) 2020-10-16
IL276286A (en) 2020-09-30
US20190263934A1 (en) 2019-08-29
NZ767453A (en) 2025-03-28
CO2020010269A2 (es) 2020-12-10
JP2026021377A (ja) 2026-02-10
IL276286B1 (en) 2025-03-01
RU2020128177A (ru) 2022-02-28
SG11202006905YA (en) 2020-08-28
CN119350481A (zh) 2025-01-24
TW201940512A (zh) 2019-10-16
MX2025009543A (es) 2025-09-02
KR20200115568A (ko) 2020-10-07
IL318916A (en) 2025-04-01
JP7399880B2 (ja) 2023-12-18
JP2021511830A (ja) 2021-05-13
CN111788221B (zh) 2026-02-13
AU2019212638B2 (en) 2025-04-03
CA3089602A1 (en) 2019-08-01
PH12020551134A1 (en) 2021-05-31
IL276286B2 (en) 2025-07-01
AU2025204826A1 (en) 2025-07-17
JP2024026255A (ja) 2024-02-28
WO2019147973A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
MX2020007882A (es) Variantes fc con unión mejorada a fcrn y semivida prolongada.
ZA202409972B (en) Fcrn antagonists and methods of use
EA202092093A1 (ru) Композиции и способы перепрограммирования tcr с применением слитых белков
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
MX2021010354A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
EA202091198A1 (ru) Полипептиды, содержащие домен d, и их применение
MX2023007211A (es) Anticuerpos antimiostatina y metodos de uso.
EA202091166A1 (ru) ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
MX2020010235A (es) Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
MY202559A (en) Anti-ctla-4 antibody and use thereof
MY189425A (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
CR20230026A (es) Proteínas de fusión gdf15 y usos de estas (divisional 2018-0532)
SG10201808158UA (en) Site-specific glycoengineering of targeting moieties
MX2018009375A (es) Genes del factor viii optimizados.
CR20210370A (es) Neoantígenos prostáticos y sus usos
EA202091239A1 (ru) Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение
MX381726B (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
EA201990822A1 (ru) Иммуномодулирующие слитые белки
CO2025017440A2 (es) Anticuerpos de dominio único modificados
EA201792274A1 (ru) Слитые молекулы вариант iii рецептора эпидермального фактора роста-мезотелин и способы их применения
EA201690634A1 (ru) Новая гетеро-трансгликозилаза и ее применение
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
AU2018273799A1 (en) Novel murine parvovirus and uses therefor